September 2005 in “Revue de Stomatologie et de Chirurgie Maxillo-faciale”
1 citations
,
March 2015 in “Journal of the European Academy of Dermatology and Venereology” This letter to the editor shares a case study of lentiginous melanoma that appears clinically malignant but histopathologically benign, involving the BRAFV600R mutation.
January 2024 in “Wiadomości Lekarskie” This study reports that while primary treatment for uveal melanoma has a very high success rate, treating distant metastases, particularly in the liver, remains challenging. Tebentafusp, dependent on HLA-A expression, is the first drug to extend patient survival.
September 2023 in “Journal of the American Academy of Dermatology” In this study of pediatric melanocytic lesions, researchers at Massachusetts General Hospital observed no concurrent BAP1 loss and BRAFV600E positivity, characteristics of adult BIMT, suggesting that these tumors may develop at a later age rather than in childhood.
May 2019 in “CINECA IRIS Institutial Research Information System (University of Genoa)” This study found that patients with the MITF p.E318K variant are more likely to develop multiple primary melanomas and dysplastic nevi with uncommon dermoscopic patterns compared to non-carriers.